Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Unoprostone isopropyl is a synthetic docosanoid and a structural analogue of an inactive biosynthetic cyclic derivative of arachidonic acid (13,14-dihydro-15-keto-prostaglandin F2α). It acts as a prodrug that, upon ocular administration, lowers intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The drug primarily increases the outflow of aqueous humor through the trabecular meshwork and possibly via the uveoscleral pathway. Its mechanism may involve stimulation of calcium (Ca2+)-activated BK channels and ClC-2 chloride channels in the trabecular meshwork. Unoprostone isopropyl does not significantly affect aqueous humor production or systemic cardiovascular/pulmonary function[1][2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on unoprostone isopropyl.